Through a simple blood test, PrismRA could predict non-response to anti-TNF therapies in patients with rheumatoid arthritis, allowing RA patients to receive the right drug from day one.
About 90% of RA patients who fail a DMARD like methotrexate are prescribed anti-TNF biologic therapies, but only about one in three RA patients will respond to these drugs. Those who do not respond are exposed to potentially dangerous side effects all while their diseases progress and they waste money on ineffective prescription costs. Currently, there is no tool to predict which patient will respond to which treatment today, so patients are being treated uniformly rather than based on their unique disease biology.
It’s time to stop treating all RA patients the same and create a treatment road map unique to each individual. By joining the trial and giving a simple blood sample, you can continue to follow your standard of care and help us get PrismRA one step closer today, stopping RA patients from cycling through ineffective treatments tomorrow.
Determine the predictive ability of PrismRA to identify anti-TNF therapy non-responders in female and/or all rheumatoid arthritis patients with moderate or high disease activity using standard clinical outcome measures